chrisvoncsefalvay/vaers-outcomes huggingface dataset:
High Blood Pressure 2 hour's after booster 164/107; High Blood Pressure 2 hour's after booster 164/107; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 19Oct2021 11:00 (Lot number: EW0181) at the age of 66 year as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Inflammation of shoulder" (unspecified if ongoing). Family history included: "A-Flutter", start date: 11Mar2021 (unspecified if ongoing), notes: 08Apr2021 had ablation to correct atrial  flutter. Concomitant medication(s) included: IBUPROFEN [IBUPROFEN SODIUM] taken for inflammation (ongoing). Vaccination history included: Bnt162b2 (Dose:1, Date/Time (24hr): 10Feb2021 and time: 15:00 GMT, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: EL9265), administration date: 10Feb2021, when the patient was 66 years old, for COVID-19 Immunization, reaction(s): "BP 194/110", "I felt extremely unwell", "no appetite", "felt sick", "No energy", "double vision"; Bnt162b2 (Dose: 2, Date/Time (24hr): 03Mar2021 and time: 15:00 GMT, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: EN6202), administration date: 03Mar2021, when the patient was 66 years old, for COVID-19 Immunization, reaction(s): "High blood pressure". The following information was reported: IMMUNISATION (non-serious) with onset 19Oct2021 11:00, outcome "unknown", HYPERTENSION (non-serious) with onset 19Oct2021 13:00, outcome "recovered" (02Nov2021) and all described as "High Blood Pressure 2 hour's after booster 164/107". Relevant laboratory tests and procedures are available in the appropriate section.  Follow-up attempts are completed. No further information is expected.
Small left para midline pontine acute infarction with the basilar artery territory infarction
Large, red area with swelling and fever on right deltoid and bicep about 2 inches below injection site. Medium, painful knots along right clavicle. Both starting 4 days after vaccine.
Per phone conversation with mother on 6/25/11 patient had complained of pain at injection site x 2 weeks after getting HPV; not eating well. Not seen by a provider in our practice (out of town).
No additional adverse events; administration of improperly stored PROQUAD; This spontaneous report was received from a physician who refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 03-AUG-2021, the patient was vaccinated with improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) recombinant human albumin (rHA) (lot # U006314, expiration date: 24-AUG-2022) (strength, route of administration and exact dose were not provided) for prophylaxis. No adverse events were reported. According to the reporter, the temperature excursion was 45.3 degrees Fahrenheit for a time frame of 17 hours on an unspecified date, without any previous temperature excursion.
Sore neck all sides for 2 weeks TYLENOL 100 m 4 x daily for week and 500 after.
Information has been received from a physician concerning a 20 month old male with no known pre-existing allergies, birth defects or medical conditions, who on 29-JAN-2007, was vaccinated with a subcutaneous dose of varicella virus vaccine live (Oka/Merck) ("lot # 08047"). The patient also received on an unreported date a subcutaneous dose in the right of measles virus vaccine live (Enders-Edmonston) (lot # "08047"). There was no reported illness at the time of the vaccination. It was reported that there was no adverse events from previous vaccinations. On 22-SEP-2007, the patient developed shingles (herpes zoster). "It manifested in a typical manner at the upper extremity to the arm with little vesicles." The patient was seen by the physician and therapy was initiated with acyclovir. Current patient status was not reported. No product quality complaint was reported. No further information was available. Additional information received from the physician's office reported that the treatment also included calamine lotion. No diagnostic test or laboratory studies were reported. It was reported that around 01-OCT-2007, the patient had recovered. Additional information has been requested.
The patient developed symptomatic COVID-19 pneumonia, moderate to severe, requiring hospitalization for medication, supplemental oxygen and close monitoring. Symptoms onset is not certain but appears at the earliest to have been on April 22. Please note that he received both doses of Pfizer mRNA COVID-19 vaccine, the second dose on 2/17/2021. Also note that the form is not allowing me to fill in hospital information in itme #21. Hospital and address as above. Today 5/8/2021 is day 4 of hospitalization. other meds (form did not allow followup here) metformin myiophendate metoprolol nifedipine simvastatin tacrolimus tamsulosin
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021 at 4:13 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 20-Mar-2021 at 4:13 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 67.89.  No concomitant medications were reported.  Batch number 031A21A administered on 20-Mar-2021 with temperature 34 degrees Fahrenheit at 09:00 AM and 37 degrees Fahrenheit at  10:00 AM. This vial was moved to fridge on 09-Mar-2021 and beyond use date for the vial was reported as 08-Apr-2021. Product moved to clinic on 20-Mar-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  No treatment medications were reported.
No additional AE; VARIVAX was delivered on 07JUN2022 after the receive by date of 06JUN2022 and was administered to a patient; This spontaneous report was received from a medical technologist lab manager and referred to a patient of unknown age and gender. the patient's concurrent conditions, medical history, and concomitant therapies were not reported. There was no information regarding the patient's allergies or drug reactions.  On 07-JUN-2022, varicella virus vaccine live (oka/merck) (VARIVAX) was delivered after the received by the date of 06-JUN-2022. On 15-JUN-2022, the patient was vaccinated with the improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) (strength, dose, dose number, route of administration and anatomical location were not reported; valid lot number: W002599 with an expiration date: 24-JAN-2024) for prophylaxis (product storage error). No additional adverse event (AE) was reported (no adverse event). There was no reported previous temperature excursion.
It was reported that a 2 year old male received a Fluzone SV '99-'00 vaccination on 11/16/99. Approx. 4-6 hours later, the pt developed a fever of 105F and an asthma attack that required emergency treatment. From additional information received on 12/15/99, it was reported that the pt was treated with nebulizer at home and that the pt recovered.
Heart arrhythmia; This is a spontaneous report from a contactable consumer or other non hcp. A 60-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EP7533 expiry date was not reported) via an unspecified route of administration at arm left on 29Jun2021 09:30 (at the age of 60-years-old) as a dose 2,single dose for covid-19 immunisation. Patient had history of allergies from an unknown date and unknown if ongoing known. Concomitant medication(s) included gabapentin (GABAPENTIN) taken for an unspecified indication, start and stop date were not reported. Patient received first dose of BNT162B2 (Lot number: ER8733 expiry date was not reported) via unspecified route of administration at left arm 08Jun2021 01:30 PM as a single dose for covid-19 immunisation. Prior to the vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 30Jun2021 the patient experienced heart arrhythmia (medically significant). Therapeutic measures were taken as a result of heart arrhythmia (arrhythmia) was Zio Heart Monitor. Outcome of the event was not recovered.  Follow-Up (23Jul2021): Follow-up attempts are completed. No further information is expected.
Redness, pain, warm to touch on right deltoid after injection - (Parent) Patient instructed to use ice pack 4x/day for 1-2 days, OTC CHILDREN'S BENADRYL in the evening and to go to the ER if worsening allergic reaction symptoms develop per PA-C.
its been 70 days since from the first dose and wanted to know should they give him his second dose now or do they need to start over the series; tested positive for covid; tested positive for covid; This is a spontaneous report from a contactable pharmacist. A 72-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number, expiration date were not reported ), dose 1 via an unspecified route of administration on 25Jan2021 as single dose for COVID-19 immunisation. Medical history included disable. Concomitant medications were not reported. On an unspecified date in Feb2021, the patient tested positive for COVID. The pharmacist stated its been 70 days since from the first dose and wanted to know should they give him his second dose now or do they need to start over the series. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on Feb2021. Outcome of the events was unknown.   Information on the lot/batch number has been requested.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the event cov id 19 ____ and the suspect drug _BNT162B2___.
4hr post vax pt exp aching;6hr post vax pt exp trembling, shaking followed by rash all over torso;
Fever and chills beginning day of vaccination, resolved 3 days post-vaccination. No treatment required.
Information has been received on 19-FEB-2018 regarding a case in litigation from a lawyer and a male patient of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. The patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route on or about 27-FEB-2013, as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended. Instead the patient contracted a persistent strain of shingles. On or about 26-NOV-2014, the patient was treated by a nurse practitioner for the onset of a severe and painful vesicular rash, which was diagnosed as a shingles outbreak. The patient was prescribed acyclovir, valacyclovir and prednisone for management of his painful symptoms. As a direct and proximate result of the defective ZOSTAVAX, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Three days post-vax the patient ran a fever of 104.7F and was irritable. The patient did not sleep well for 2-3 more days.
Malignant neoplasm of splenic flexure; Procedures: Laparoscopic assisted transverse colectomy. Recovered in hospital. Hospital admission within 6 weeks of receiving the COVID vaccine.
Menstrual changes, including lower back cramping, abnormal spotting, and bleeding after intercourse
I'm have a fever of 101 after the 2nd shot of moderna, it's been more than a day; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (I'm have a fever of 101 after the 2nd shot of moderna, it's been more than a day) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (I'm have a fever of 101 after the 2nd shot of moderna, it's been more than a day). At the time of the report, PYREXIA (I'm have a fever of 101 after the 2nd shot of moderna, it's been more than a day) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101 (High) High.         For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  Concomitant product use was not provided by the reporter. Treatment medication use was not provided by the reporter.
This study case was received from the investigator on 15 November 2012. A 30-year-old male subject, with no past medical history, had received the following vaccinations on 20 March 2012: ACAM2000 (lot number, route and site not reported) and anthrax vaccine (manufacturer, lot number, route and site not reported). Nine days post-vaccination on 29 March 2012, the subject experienced three episodes of moderate chest pain on three sequential days. The first two episodes noted on waking and resolved once he arose. The last episode on 31 March 2012 occurred while sitting wearing tactical gear and resolved when gear was removed. Troponin I and ECG were normal on 03 April 2012. The subject also experienced runny nose and productive cough from 23 March 2012 to 25 March 2012 and a nose bleed on 25 March 2012. All symptoms recovered. No further information was available at the time of the report. The subject's outcome was recovered. Per the investigator, this represents a case of potential myopericarditis and was referred to the study's adjudication committee for assessment. Documents held by sender: None.
Felt a systemic buzzing type sensation within 1-2 minutes.  Warm flushing sensation in my face; tongue, throat, lips felt weird; ears felt pressure sensation (most noticeable symptom).  Felt a little light headed, weak.  It was a drive through; I sat for about 12 minutes onsite, and also drove back into the facility to tell them I had a mild reaction and sat 10 more minutes.  I was home in 10 minutes and took benadryl immediately.
Timeline: 4/22: Pfizer Dose 2 Covid Vaccine; 5/11: L wrist dropped and numb, all L fingers unable to lift and numb; 5/14: toes burning (felt on fire) and itching, legs felt odd w/ pins and needles spasms and cramps; 5/17: became aware of lack of sensation in legs/feet at physician office; 5/20: ER visit b/c R fingers paralysis began and lightheaded--scared. MRI's performed--no tumors or lesions from notes; 5/24: EMG. Nothing notable. Too soon as Neuro indicated. Neuro Disinterested in anything other than left arm as I expressed; 6/3: Consult with. Last communication as follows: 6/11/2021: Hi mam,  I would not do it earlier than the last week of June for a more accurate study. Also, in regards to the vaccination- unfortunately, there is no way to confirm whether it definitely did or didn't play a role, but you may be right and that it is part of this picture for you. Unfortunately, we are at a place right now where the medical community is still learning about the potential side effects since it is a new vaccination. We don't yet know exactly how long after the vaccination we can expect side effects to occur and how long they are expected to last. The good news is that it doesn't alter your treatment course either way. The same holds true for those that suffer from headaches after the vaccination or even covid-19 infection. The headaches are treated the same as regular tension headaches/migraines. If there is a component of a vaccine side effect we do expect time to help heal that as well, but I would definitely continue with our plan to proceed with the nerve study, PT, and avoiding positions that cause nerve compression.    Sincerely, PA-C   On 6/7/2021 Physician also wrote: Guillain Barre Syndrome can happen after vaccinations and is something that I did consider for you. I do not think that your symptoms and exam align too well with it though. The "text book" or "hallmark" presentation is ascending weakness, numbness, and tingling. It typically starts in the feet and can work its way all the way up to the hands and respiratory muscles. The pattern of your symptoms is not quite consistent with this.
Constant throwing up and went into a stroke; Constant throwing up and went into a stroke; This is a spontaneous report from a contactable consumer (patient). An 80-year-old female patient received the first dose of BNT162B2 (PFIZER COVID-19 VACCINE, lot number: EWO151), at the age of 80 years old, in right arm on 02Apr2021 12:45 at single dose for covid-19 immunisation.  Medical history included chronic obstructive pulmonary disease (COPD). The patient was not pregnant at time of vaccination. The patient was not diagnosed with covid-19 prior to vaccination. The patient received any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to vaccination. The patient experienced constant throwing up and went into a stroke on 01May2021 10:00. The patient was hospitalized due to the events. The patient had not been tested for covid-19 since the vaccination. Therapeutic measures were taken as a result of constant throwing up and went into a stroke. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Fever 105 started after 1 pm Thursday May 27 vaccines given 5/27/04 at 11AM.
Narrative: 48 yo female patient states felt dizziness,fatique,bilateral leg weakness after vaccination Monitored at the facility and symptoms resolved.
Hypoxia, admitted.  TX includes: O2, remdesivir, dexamethasone, IVF
103.1 Fever, severe shakes from fever, headache, joint pain, nausea
This case was reported by a consumer via call center representative and described the occurrence of heart rate increased in a 75-year-old female patient who received SHINGRIX. On 24th January 2018, the patient received SHINGRIX. In January 2018, less than a week after receiving SHINGRIX, the patient experienced heart rate increased and injection site pain. On an unknown date, the outcome of the heart rate increased and injection site pain were unknown. It was unknown if the reporter considered the heart rate increased and injection site pain to be related to SHINGRIX. Additional details were provided as follows: A day after vaccination, the patient had contacted in regards to a slightly elevated heart rate and also mentioned she was a little sore at the injection site. Contact details of the prescribing physician was provided, however unsure if the details corresponded to vaccine administration details.
Pityriasis rosea beginning later that day. I noticed the herald patch about a week earlier but I assumed it was a bug bite. Rash has since expanded (and is currently still spreading) across entire abdomen area beginning at lower help and centralized on chest and back.
Gross hematuria started approximately 31 hours after second vaccine. Developed fever, chills and body aches 12 hrs after vaccine, took Tylenol and Motrin to alleviate fever and body aches. Sought care in urgent care for gross hematuria. No treatment provided, was referred for CT scan and urology evaluation.
Three days following  Moderna COVID-19 Vaccine EUA, a red, itchy rash developed on chest, thighs, and buttocks.
Patient developed a pallor and ambulation became more difficult. Patient escorted to seating area and vitals were taken. Given water and crackers and symptoms resolved within 30 minutes.
At 10:50 am Patient complained of feeling light headed and having and usual feeling heart beat. V/S BP 129/85, HR 73. Gave patient a bottle of water and advised to sit for additional 15 minutes. 11:10 am patient stated she feels ok. to leave. BP 115/90 and HR 93.